- Home
- PHVS vs NRK Comparison
PHVS vs NRK Comparison
Compare PHVS & NRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHVS
- NRK
- Stock Information
- Founded
- PHVS 2015
- NRK 2002
- Country
- PHVS Switzerland
- NRK United States
- Employees
- PHVS N/A
- NRK N/A
- Industry
- PHVS Biotechnology: Pharmaceutical Preparations
- NRK Trusts Except Educational Religious and Charitable
- Sector
- PHVS Health Care
- NRK Finance
- Exchange
- PHVS Nasdaq
- NRK Nasdaq
- Market Cap
- PHVS 980.3M
- NRK 922.1M
- IPO Year
- PHVS 2021
- NRK N/A
- Fundamental
- Price
- PHVS $18.60
- NRK $9.87
- Analyst Decision
- PHVS Buy
- NRK
- Analyst Count
- PHVS 6
- NRK 0
- Target Price
- PHVS $37.17
- NRK N/A
- AVG Volume (30 Days)
- PHVS 35.9K
- NRK 187.3K
- Earning Date
- PHVS 08-13-2025
- NRK 01-01-0001
- Dividend Yield
- PHVS N/A
- NRK 4.10%
- EPS Growth
- PHVS N/A
- NRK N/A
- EPS
- PHVS N/A
- NRK N/A
- Revenue
- PHVS N/A
- NRK N/A
- Revenue This Year
- PHVS N/A
- NRK N/A
- Revenue Next Year
- PHVS N/A
- NRK N/A
- P/E Ratio
- PHVS N/A
- NRK N/A
- Revenue Growth
- PHVS N/A
- NRK N/A
- 52 Week Low
- PHVS $11.51
- NRK $8.95
- 52 Week High
- PHVS $25.50
- NRK $11.09
- Technical
- Relative Strength Index (RSI)
- PHVS 60.00
- NRK 56.70
- Support Level
- PHVS $16.72
- NRK $9.86
- Resistance Level
- PHVS $17.53
- NRK $9.94
- Average True Range (ATR)
- PHVS 0.93
- NRK 0.05
- MACD
- PHVS 0.07
- NRK 0.03
- Stochastic Oscillator
- PHVS 92.86
- NRK 78.30
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.
About NRK Nuveen New York AMT-Free Quality Municipal Income Fund
Nuveen New York AMT-Free Quality Municipal Income Fund is a closed-end investment company. Its investment objective is to provide current income exempt from regular federal, New York State, and New York City income taxes and from the federal alternative minimum tax applies to individuals and to enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.